Table 2.
Protease | Developer | Description | Development stage |
---|---|---|---|
Desmoteplase | Lundbeck | Recombinant bat t-PA, rDSP | Phase III |
FIX–Fc | Biogen Idec | Fusion of an Fc fragment of IgG with FIX | Phase III |
FVIIa analogue, NN1731 | Novo Nordisk | Fast-acting FVIIaV158D/E296V/M298Q–FVIIa | Phase II |
GlycoPEGylated FVIIa, NN7128 | Novo Nordisk | Long-acting FVIIa derivative | Phase II |
FIX | St. Jude Children’s Research Hospital | Adeno-associated viral vector expressing human FIX (scAAV2/8-LP1-hFIXco) |
Phase I/II |
GlycoPEGylated FIX, NN7999 | Novo Nordisk | Long-acting FIX derivative | Phase I |
FIX–albumin fusion | CSL Behring | FIX fused with albumin | Phase I |
GlycoPEGylated FVIIa, NN7129 | Novo Nordisk | Subcutaneous long-acting FVIIa derivative | Phase I |
BAY 86–6150 | Bayer Schering Pharma/Maxygen | Recombinant FVIIa variant, developed with gene shuffling technology |
Phase I |
FIX | Children’s Hospital of Philadelphia | Adeno-associated viral vector expressing human FIX (AAV2-hFIX) |
Phase I |
FVIIa analogue | Pfizer/Catalyst Biosciences | Engineered FVIIa | Preclinical |
PEGylated FIX | Baxter International | Long-acting rFIX derivative | Preclinical |
rFVIIa–albumin fusion | CSL Behring | FVIIa fused with albumin | Preclinical |
FVIIa–CTP, MOD-5023 | Prolor Biotech | Long-acting FVIIa analogue | Preclinical |
FXa analogue | Pfizer/Children’s Hospital of Philadelphia | Engineered FXa | Preclinical |
Engineered FIX and other proteases | Bayer Schering Pharma/Direvo | Therapase technology, proteases with altered specificity and inhibitor resistance |
Preclinical |